Publications by authors named "Mohamed Seto Camara"
Introduction: With the development of therapeutics and vaccine against Ebola virus disease (EVD), the question of post-exposure prophylaxis for high-risk contact has emerged. Immunotherapies (monoclonal antibodies [mAbs]) recently validated for treating infected patients appear to be a good candidate for protecting contacts.
Design: During the tenth EVD outbreak in the Democratic Republic of the Congo, we have administrated mAbs (Mab114 or REGN-EB3) to high and intermediate-risk contacts of EVD patients.
Correction: Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea.
Daouda Sissoko Cedric Laouenan Elin Folkesson Abdoul-Bing M'Lebing Abdoul-Habib Beavogui Alseny-Modet Camara Mohamed Seto Camara Diarra Camara Fodé Saydou Camara
PLoS Med
April 2016
[This corrects the article DOI: 10.1371/journal.pmed.
View Article and Find Full Text PDFExperimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea.
Daouda Sissoko Cedric Laouenan Elin Folkesson Abdoul-Bing M'Lebing Abdoul-Habib Beavogui Alseny-Modet Camara Mohamed Seto Camara Diarra Camara Fodé Saydou Camara
PLoS Med
March 2016
Article Synopsis
- Ebola virus disease (EVD) is highly fatal, and during the 2014 outbreak, the WHO identified favipiravir as a potential treatment, but ethical concerns prevented randomized trials.
- Instead, a multicenter non-randomized trial was conducted where all patients received favipiravir to assess its feasibility, safety, and effectiveness in treating EVD.
- Participants were selected based on specific criteria and received a set dosage of favipiravir, with the goal of gathering preliminary data to inform future research rather than establish definitive treatment guidelines.